• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Real-world patient- and caregiver-reported outcomes in advanced breast cancer.晚期乳腺癌患者及照护者报告的真实世界结局
Curr Oncol. 2018 Aug;25(4):e282-e290. doi: 10.3747/co.25.3765. Epub 2018 Aug 14.
2
Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy.晚期尿路上皮癌患者接受 PD-1/L1 抑制剂治疗后停药的临床和患者报告结局。
Clin Genitourin Cancer. 2022 Dec;20(6):543-552. doi: 10.1016/j.clgc.2022.08.002. Epub 2022 Aug 6.
3
Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.贝伐珠单抗或西妥昔单抗联合方案一线或一线序贯二线治疗转移性结直肠癌患者的真实世界直接医疗成本。
Clin Colorectal Cancer. 2017 Dec;16(4):386-396.e1. doi: 10.1016/j.clcc.2017.03.014. Epub 2017 Mar 24.
4
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.接受卡马替尼治疗的 METex14 突变型晚期 NSCLC 患者的报告结果:来自 GEOMETRY mono-1 研究的结果。
Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030. Epub 2022 Dec 10.
5
Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.针对不可切除转移性结直肠癌的血管内皮生长因子和/或表皮生长因子受体单克隆抗体治疗的序贯方案的经济学结局。
J Med Econ. 2014 Feb;17(2):99-110. doi: 10.3111/13696998.2013.864973. Epub 2013 Dec 3.
6
Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting.在真实世界环境中,一项针对晚期非小细胞肺癌患者的前瞻性横断面患者调查:健康相关生活质量和效用。
J Thorac Oncol. 2013 Aug;8(8):997-1003. doi: 10.1097/JTO.0b013e318299243b.
7
Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA.美国转移性胃癌患者一线使用曲妥珠单抗后的真实世界治疗模式及经济负担
Drugs Real World Outcomes. 2023 Sep;10(3):395-404. doi: 10.1007/s40801-023-00378-y. Epub 2023 Aug 4.
8
Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.慢性髓性白血病中酪氨酸激酶抑制剂治疗失败的经济负担因治疗线数增加而加重。
Curr Med Res Opin. 2016;32(2):289-99. doi: 10.1185/03007995.2015.1120189. Epub 2015 Nov 30.
9
Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation.一线刺猬信号通路抑制剂停用后基底细胞癌患者的真实世界治疗模式和结局
Dermatol Ther (Heidelb). 2022 May;12(5):1211-1224. doi: 10.1007/s13555-022-00724-y. Epub 2022 May 4.
10
Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.化疗在美国老年转移性膀胱癌患者中的真实世界疗效
Bladder Cancer. 2018 Apr 26;4(2):227-238. doi: 10.3233/BLC-170149.

引用本文的文献

1
Quality of life of patients treated for stage IV breast cancer. Multidimensional assessment and examination of determining factors.IV期乳腺癌患者的生活质量。多维度评估及决定因素分析
Contemp Oncol (Pozn). 2024;28(4):350-357. doi: 10.5114/wo.2024.147006. Epub 2025 Jan 15.
2
Caregiver Burden of Palliative Cancer Patients: A Cross-Cultural Perspective.姑息治疗癌症患者的照顾者负担:跨文化视角
Florence Nightingale J Nurs. 2024 Feb 28;32(1):110-115. doi: 10.5152/FNJN.2024.23058.
3
Caregiver Stress Is Improved and Sustained Following Transcatheter Aortic Valve Replacement.经导管主动脉瓣置换术后,照顾者压力得到改善并持续缓解。
Palliat Med Rep. 2023 Feb 24;4(1):56-58. doi: 10.1089/pmr.2022.0064. eCollection 2023.
4
Quality of Life vs. Supportive Care Needs for Oral Cancer Caregivers: Are They Related?生活质量与口腔癌照顾者的支持性护理需求:它们相关吗?
Curr Oncol. 2023 Feb 1;30(2):1733-1744. doi: 10.3390/curroncol30020134.
5
Living with Advanced Breast Cancer: A Descriptive Analysis of Survivorship Strategies.与晚期乳腺癌共存:生存策略的描述性分析
J Clin Med. 2022 Jul 10;11(14):3992. doi: 10.3390/jcm11143992.
6
To share or not to share: communication of caregiver-reported outcomes when a patient has colorectal cancer.分享与否:患者患结直肠癌时照顾者报告结局的沟通
J Patient Rep Outcomes. 2022 Feb 5;6(1):13. doi: 10.1186/s41687-022-00418-1.
7
Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.新加坡绝经前晚期乳腺癌患者初始使用瑞博西利治疗的成本效果分析。
Cancer Rep (Hoboken). 2021 Feb;4(1):e1308. doi: 10.1002/cnr2.1308. Epub 2020 Oct 21.
8
Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.在五个欧洲国家中,接受初始基于内分泌的治疗的 HR+/HER2- 晚期乳腺癌女性的真实世界患者报告结局。
BMC Cancer. 2020 Sep 7;20(1):855. doi: 10.1186/s12885-020-07294-2.
9
Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry.真实世界中晚期乳腺癌患者的生活质量:SONABRE 登记研究。
Qual Life Res. 2020 Dec;29(12):3363-3374. doi: 10.1007/s11136-020-02604-4. Epub 2020 Aug 20.

本文引用的文献

1
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.贝伐单抗治疗HER2阴性转移性乳腺癌患者的真实世界和基于试验的成本效益分析:荷兰东南部乳腺癌联盟的一项研究
Eur J Cancer. 2017 Jul;79:238-246. doi: 10.1016/j.ejca.2017.01.027. Epub 2017 Feb 27.
2
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).第三届欧洲中学教育阶段(ESO)-欧洲肿瘤内科学会(ESMO)晚期乳腺癌国际共识指南(ABC 3)
Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544.
3
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.人表皮生长因子受体2阴性(或未知)晚期乳腺癌女性的化疗与靶向治疗:美国临床肿瘤学会临床实践指南
J Clin Oncol. 2014 Oct 10;32(29):3307-29. doi: 10.1200/JCO.2014.56.7479. Epub 2014 Sep 2.
4
Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study.EQ-5D-5L 与 EQ-5D-3L 在八个患者群体中的测量性能比较:一项多国家研究。
Qual Life Res. 2013 Sep;22(7):1717-27. doi: 10.1007/s11136-012-0322-4. Epub 2012 Nov 25.
5
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.局部复发或转移性乳腺癌:ESMO临床实践指南之诊断、治疗与随访
Ann Oncol. 2012 Oct;23 Suppl 7:vii11-9. doi: 10.1093/annonc/mds232.
6
The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer. caregiver 肿瘤患者生活质量问卷(CarGOQoL):一种用于测量癌症患者照顾者生活质量的工具的开发和验证。
Eur J Cancer. 2012 Apr;48(6):904-11. doi: 10.1016/j.ejca.2011.09.010. Epub 2011 Oct 25.
7
Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.利用真实世界数据进行覆盖范围和支付决策:药物经济学与结果研究国际协会(ISPOR)真实世界数据特别工作组报告
Value Health. 2007 Sep-Oct;10(5):326-35. doi: 10.1111/j.1524-4733.2007.00186.x.
8
Self-reported utilization of health care services: improving measurement and accuracy.自我报告的医疗保健服务利用情况:改进测量方法与准确性
Med Care Res Rev. 2006 Apr;63(2):217-35. doi: 10.1177/1077558705285298.
9
The validity and reproducibility of a work productivity and activity impairment instrument.一种工作效率和活动能力受损评估工具的有效性和可重复性。
Pharmacoeconomics. 1993 Nov;4(5):353-65. doi: 10.2165/00019053-199304050-00006.
10
EuroQol--a new facility for the measurement of health-related quality of life.欧洲生活质量量表——一种衡量健康相关生活质量的新工具。
Health Policy. 1990 Dec;16(3):199-208. doi: 10.1016/0168-8510(90)90421-9.

晚期乳腺癌患者及照护者报告的真实世界结局

Real-world patient- and caregiver-reported outcomes in advanced breast cancer.

作者信息

Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Zanotti G, Tran T, Mates M, Lemieux J, Chabot P, Prady C, Couture F, Lachaine J

机构信息

PeriPharm Inc., Montreal, QC.

Pfizer Inc., New York, NY, U.S.A.

出版信息

Curr Oncol. 2018 Aug;25(4):e282-e290. doi: 10.3747/co.25.3765. Epub 2018 Aug 14.

DOI:10.3747/co.25.3765
PMID:30111973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6092048/
Abstract

BACKGROUND

Advanced breast cancer (abc) represents a substantial burden for patients and caregivers. In the present study, we aimed to estimate quality of life (qol), utility, productivity loss, pain, health care resource utilization, and costs for patients with abc, and qol, utility, and productivity loss for their caregivers.

METHODS

This multicentre prospective non-interventional study was conducted in Canada. Eligible participants were postmenopausal women with estrogen receptor-positive, her2-negative unresectable abc and their caregivers. Validated questionnaires were used to measure qol, utility, productivity loss, and pain. Patients and caregivers were classified into 4 health states typically used in oncology economic modelling: first-line progression-free (1l-pf), first-line progressive disease (1l-pd), second- or subsequent-line progression-free (≥2l-pf), and second- or subsequent-line progressive disease (≥2l-pd).

RESULTS

Most patients and caregivers accepted to participate, with total recruitment of 202 patients and 78 caregivers. Compared with patients in pf, patients in pd had lower mean qol scores (52.9 ± 29.9 for 1l-pd vs. 68.2 ± 23.2 for 1l-pf, and 54.0 ± 23.6 for ≥2l-pd vs. 66.0 ± 22.1 for ≥2l-pf), lower mean utility values (0.64 ± 0.22 for 1l-pd vs. 0.73 ± 0.20 for 1l-pf, and 0.65 ± 0.25 for ≥2l-pd vs. 0.74 ± 0.18 for ≥2l-pf), and greater productivity loss (39.4 ± 27.7 for 1l-pd vs. 27.5 ± 30.1 for 1l-pf, and 37.6 ± 29.2 for ≥2l-pd vs. 32.0 ± 29.0 for ≥2l-pf). Compared with caregivers of patients in pf, caregivers of patients in pd had lower qol scores and utility values, and greater productivity loss.

CONCLUSIONS

Study results indicate that, for patients and caregivers, pd health states are associated with a deterioration of qol and utility and a decrease in productivity in both 1l and ≥2l.

摘要

背景

晚期乳腺癌(ABC)给患者及其照料者带来了沉重负担。在本研究中,我们旨在评估ABC患者的生活质量(QoL)、效用、生产力损失、疼痛、医疗资源利用和成本,以及其照料者的QoL、效用和生产力损失。

方法

这项多中心前瞻性非干预性研究在加拿大进行。符合条件的参与者为绝经后雌激素受体阳性、人表皮生长因子受体2阴性不可切除ABC患者及其照料者。使用经过验证的问卷来测量QoL、效用、生产力损失和疼痛。患者和照料者被分为肿瘤学经济模型中通常使用的4种健康状态:一线无进展(1L-PF)、一线疾病进展(1L-PD)、二线或后续线无进展(≥2L-PF)和二线或后续线疾病进展(≥2L-PD)。

结果

大多数患者和照料者同意参与,共招募了202名患者和78名照料者。与处于PF状态的患者相比,处于PD状态的患者平均QoL得分较低(1L-PD为52.9±29.9,1L-PF为68.2±23.2;≥2L-PD为54.0±23.6,≥2L-PF为66.0±22.1),平均效用值较低(1L-PD为0.64±0.22,1L-PF为0.73±0.20;≥2L-PD为0.65±0.25,≥2L-PF为0.74±0.18),生产力损失更大(1L-PD为39.4±27.7,1L-PF为27.5±30.1;≥2L-PD为37.6±29.2,≥2L-PF为32.0±29.0)。与处于PF状态患者的照料者相比,处于PD状态患者的照料者QoL得分和效用值较低,生产力损失更大。

结论

研究结果表明,对于患者及其照料者而言,PD健康状态与1L和≥2L的QoL和效用恶化以及生产力下降相关。